Biomarkers

Although there are numerous crucial applications for biomarkers in clinical practise and product testing, most of them have not been proven to accurately predict clinical outcomes. Several of these case studies demonstrate how promising phase 2 biomarker data does not always transfer into successful product performance. Phase 2 testing of medications for disorders including AD (semagacestat), cardiac disease (aliskiren, darapladib, torcetrapib), Staph infection (V710 vaccine), and herpes infection (herpes simplex) revealed positive biomarker results (HSV-2 vaccine). In phase 3 trials, these investigational goods were not shown to be productive.


    Related Conference of Biomarkers

    July 27-28, 2026

    19th World Drug Delivery Summit

    Paris, France
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    September 14-15, 2026

    6th International Conference on Pharmaceutical Chemistry

    Paris, France
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 26-27, 2026

    5th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 26-27, 2026

    5th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    December 14-15, 2026

    5th Global Summit on Pharmaceutical Research

    Paris, France
    January 26-27, 2027

    22nd Annual Meet on Pharmaceutical Sciences

    Paris, France
    April 27-28, 2027

    10th European Biopharma Congress

    Paris, France

    Biomarkers Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in